Allogene Therapeutics, Inc. (ALLO) Free Cash Flow
Allogene Therapeutics, Inc. (ALLO) free cash flow history and trends. Track FCF in Excel with MarketXLS.
Free Cash Flow Data
| Period | Free Cash Flow (USD) |
|---|---|
| 2018-12-31 | -$47.89M |
| 2019-12-31 | -$188.14M |
| 2020-12-31 | -$181.05M |
| 2021-12-31 | -$206.26M |
| 2022-12-31 | -$225.71M |
| 2023-12-31 | -$239.25M |
| 2024-12-31 | -$200.99M |
| 2025-12-31 | -$149.63M |
How ALLO compares with sector peers
| Symbol | Company | Free cash flow (latest fiscal year) |
|---|---|---|
| FLGT | Fulgent Genetics Inc. | -$124.21M |
| VYGR | Voyager Therapeutics Inc. | -$135.06M |
| VSTM | Verastem Inc. | -$147.13M |
| GOSS | Gossamer Bio Inc. | -$171.34M |
| ALEC | Alector Inc. | -$184.07M |
These are five companies in the same sector as ALLO with a comparable annual free cash flow. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Allogene Therapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Free_Cash_Flow("ALLO", 2025, "")
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | ALLO | $1.46 | +4.29% | 10.60M |
| 3 | ||||
| 4 | ||||
| 5 |